Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Surgery
Volume 2015, Article ID 431943, 4 pages
Case Report

Aggressive Behaviour of Metastatic Melanoma in a Patient with Neurofibromatosis Type 1

1School of Medicine and Medical Science, University College Dublin, Belfield, Dublin 4, Ireland
2Conway Institute of Biomedical and Biomolecular Research, University College Dublin, Belfield, Dublin 4, Ireland
3Department of Pathology, St. Vincent’s University Hospital, Elm Park, Dublin 4, Ireland
4Department of Cardiothoracic Surgery, St. Vincent’s University Hospital, Elm Park, Dublin 4, Ireland

Received 15 October 2014; Revised 11 March 2015; Accepted 16 March 2015

Academic Editor: Francesco Petrella

Copyright © 2015 Robert W. Foley et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Malignant melanoma is a common skin neoplasm bearing poor prognosis when presenting with metastases. Rarely melanoma metastases present without an identifiable primary cutaneous lesion despite exhaustive workup. We describe the case of a solitary lung metastasis in a patient with neurofibromatosis type 1 without an identifiable primary tumour. The rapid progression of this malignant neoplasm that led to the patient’s death within 1 year is described.

1. Case Presentation

A 65-year old man with neurofibromatosis type 1 (NF1) underwent a chest X-ray following a three-week history of cough productive of white sputum. He was otherwise asymptomatic but had a 30-pack-year smoking history. The radiograph revealed a solitary coin lesion of the right lower lobe. The patient underwent a CT scan which demonstrated a 3.3 cm right lower lobe lesion, separate to the pleura and suspicious for primary lung carcinoma (Figure 1). A CT guided biopsy of the mass was obtained and histological examination demonstrated a deposit of large nucleolated epithelioid cells with pigment, positive for S100 and Melan A (Figure 2). The patient was discussed at a multidisciplinary meeting and a provisional diagnosis of metastatic melanoma was made.

Figure 1: CT imaging of lung metastasis in coronal (a) and axial (b) planes.
Figure 2: Histological analysis of lung biopsy. Tissue was negative for primary lung cancer ((a) CK stain and (b) TTF-1 stain) and was positive for melanoma ((c) Melan A stain and (d) S100 stain).

Physical examination to establish the primary lesion was complicated by the presence of numerous neurofibromas and hyperpigmented café au lait spots, and the search ultimately proved unsuccessful. A PET/CT demonstrated a focal nodule in the right lung and several other masses with poor radiotracer uptake consistent with neurofibromas. Crucially the scan did not elicit a primary melanoma. The patient’s ECOG performance status was 0 and therefore VATS metastasectomy with clear histological margins was performed. The tissue was stained for the BRAF V600 mutation but was negative and thus, the prescription of Vemurafenib was not deemed beneficial. Because the risk of systemic relapse was extremely high, the patient was followed with active surveillance.

The patient had undergone two surgical resections of large superficial plexiform neurofibromas 20 years ago. After the PET scan had proved negative, the possibility that these operations had removed the primary melanoma was considered. While attending the plastic surgery department 2 months after his VATS procedure for removal of an elbow neurofibroma, a pigmented lesion of the patient’s skin, buried within his beard, was noted (Figure 3). Histologic analysis following excision demonstrated a superficial spreading malignant melanoma. It was Clark’s level 4 tumour with a Breslow thickness of 1.6 cm. It was BRAF V600 mutation negative.

Figure 3: H&E stains on initial biopsy (a), metastasectomy (b), and primary melanoma excised from the neck (c).

One month after diagnosis, the patient suffered an acute stroke like episode, with subsequent CT brain indicating the presence of 6 intracranial lesions (Figure 4), compatible with metastases. The patient was treated with a course of whole brain radiotherapy and subsequently discharged to hospice care for palliative treatment. He succumbed to his illness 11 months after initial presentation, highlighting the rapid progression of this patient’s malignant melanoma.

Figure 4: CT imaging of brain metastases in the coronal (a) and axial (b) planes.

2. Discussion

NF1 patients are at increased risk of neural crest derived neoplasms [1]. Because melanocytes are derived from the embryologic neural crest, patients with NF1 have a propensity for developing this malignancy. The absence of an identifiable primary cutaneous, mucosal, or ocular melanoma in our patient raised the question of whether the tumour was a primary pulmonary melanoma or metastatic melanoma of unknown primary (MUP). Primary pulmonary melanoma is incredibly rare and is a controversial neoplasm due to unclear diagnostic criteria [2, 3]. Whereas MUP occurs in approximately 2.6% of patients presenting with metastasis, with lung second only to the lymphatic system as the most common site of occurrence [4, 5], MUP is associated with better outcomes and is generally less aggressive than non-MUP disease [6, 7].

Because melanoma is associated with late metastasis [8], it is a distinct possibility that this patient’s metastasis originated from a primary cutaneous melanoma which had been removed incidentally. Conceivably during one of his previous surgeries. It is more likely, however, that the primary melanoma in this case was the lesion found in the patient’s beard. Melanoma in NF1 is more commonly of orbital origin than the cutaneous lesion as described in this case [1]. Furthermore, cutaneous melanoma presenting with lung metastasis rarely proceeds to patient death within 1 year. Median survival in these patients is 17–50 months [9], emphasizing the rapidly progressive nature of the disease observed in our patient.

MUP should be investigated with PET/CT to locate the primary lesion and to stage the disease [10]. However the importance of a full physical examination, including oral cavity, cannot be overemphasized [11]. Similar to this case, however, it can take up to 8 months to locate the primary melanoma [12]. It is hypothesized that some lesions diagnosed as primary pulmonary melanomas are, in fact, metastases from occult primary lesions which have undergone spontaneous regression.

Regardless of the origin of the metastasis in this case, the benefit of performing metastasectomy was twofold. Firstly, a definitive diagnosis of the mass could be made as the oligometastatic lesion could have been manifesting as part of our patient’s complex syndrome (NF1), while the possibility of a sarcoma still existed. And secondly a survival advantage would be conferred to the patient. The literature suggests aggressive surgical treatment is warranted in such cases. For all patients with unknown primary melanomas, the 5-year survival rate for those undergoing surgical resection (38.8%) was significantly better than that for patients who received no treatment (19.6%) [13]. This was also endorsed by de Wilt et al., who demonstrated an increase from 22% to 42% in 5-year survival in patients with primary pulmonary melanoma undergoing metastasectomy, with a median survival of 32 months [14].

This case illustrates a primary cutaneous melanoma presenting with a solitary pulmonary metastasis in a patient with NF1. This case is unusual due to the rapid progression of this patient’s disease. Bearing in mind the close association and causative relationship of NF1 and malignant melanoma, a thorough physical examination of the patient who presents with a metastatic deposit of melanoma must be carried out in an effort to identify the primary lesion and to expedite the appropriate management strategy.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.


  1. B. Guillot, S. Dalac, M. Delaunay et al., “Cutaneous malignant melanoma and neurofibromatosis type 1,” Melanoma Research, vol. 14, no. 2, pp. 159–163, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. R. W. Wilson and C. A. Moran, “Primary melanoma of the lung: a clinicopathologic and immunohistochemical study of eight cases,” The American Journal of Surgical Pathology, vol. 21, no. 10, pp. 1196–1202, 1997. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Ost, C. Joseph, H. Sogoloff, and G. Menezes, “Primary pulmonary melanoma: case report and literature review,” Mayo Clinic Proceedings, vol. 74, no. 1, pp. 62–66, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. A. C. De Waal, K. K. H. Aben, M. M. van Rossum, and L. A. L. M. Kiemeney, “Melanoma of unknown primary origin: a population-based study in the Netherlands,” European Journal of Cancer, vol. 49, no. 3, pp. 676–683, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. K. A. Katz, E. Jonasch, F. S. Hodi et al., “Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute,” Melanoma Research, vol. 15, no. 1, pp. 77–82, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Savoia, P. Fava, S. Osella-Abate et al., “Melanoma of unknown primary site: a 33-year experience at the Turin Melanoma Centre,” Melanoma Research, vol. 20, no. 3, pp. 227–232, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. C. C. Lee, M. B. Faries, L. A. Wanek, and D. L. Morton, “Improved survival for stage IV melanoma from an unknown primary site,” Journal of Clinical Oncology, vol. 27, no. 21, pp. 3489–3495, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. N. J. Crowley and H. F. Seigler, “Late recurrence of malignant melanoma. Analysis of 168 patients,” Annals of Surgery, vol. 212, no. 2, pp. 173–177, 1990. View at Publisher · View at Google Scholar · View at Scopus
  9. D. G. Coit, “Role of surgery for metastatic malignant melanoma: a review,” Seminars in Surgical Oncology, vol. 9, no. 3, pp. 239–245, 1993. View at Google Scholar · View at Scopus
  10. P. A. Oberholzer, M. Urosevic, H. C. Steinert, and R. Dummer, “Baseline staging of melanoma with unknown primary site: the value of serum S100 protein and positron emission tomography,” Dermatology, vol. 217, no. 4, pp. 351–355, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Matsuoka, “Oral malignant melanoma detected after resection of amelanotic pulmonary metastasis,” International Journal of Surgery Case Reports, vol. 4, no. 12, pp. 1169–1172, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Shimmyo, K. Ando, A. Mochizuki, N. Kurimoto, and H. Nakamura, “A resected melanoma of the lung metastasized from an occult skin lesion: a case report,” Annals of Thoracic and Cardiovascular Surgery, vol. 20, supplement, pp. 554–557, 2014. View at Publisher · View at Google Scholar
  13. A. E. Chang, L. H. Karnell, and H. R. Menck, “The national cancer data base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society,” Cancer, vol. 83, no. 8, pp. 1664–1678, 1998. View at Google Scholar
  14. J. H. W. de Wilt, S. E. J. Farmer, R. A. Scolyer, B. C. McCaughan, and J. F. Thompson, “Isolated melanoma in the lung where there is no known primary site: metastatic disease or primary lung tumour?” Melanoma Research, vol. 15, no. 6, pp. 531–537, 2005. View at Publisher · View at Google Scholar · View at Scopus